BDX - Becton Dickinson HPV test Onclarity gets FDA nod for expanded use

• Becton, Dickinson and Company ( NYSE: BDX ) said that the U.S. Food and Drug Administration (FDA) approved BD Onclarity HPV Assay to be used with the ThinPrep Pap Test.
• The BD Onclarity HPV Assay can now be used with both BD SurePath Liquid-based Pap Test and Hologic ThinPrep Pap Test, the company added.
• BDX noted that the Onclarity test detects and identifies 14 high-risk human papillomavirus (HPV) types in a single analysis.
• "HPV31 poses the second-highest risk for cervical pre-cancer, and the BD Onclarity HPV Assay is the only FDA-approved assay that screens for it individually," said Brooke Story, worldwide president of Integrated Diagnostics Solutions for BDX.

For further details see: